Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia

References

• Gale RP, Cline MJ. High remission rate in acute myelocytic leukemia. Lancet 1977;1:497–499.
   PubMed Web of Science ®Google Scholar
• Rees JK, Sandler RM, Challener J, et al. Treatment of acute myeloid leukaemia with a triple cytotoxic regimen: DAT. Br J Cancer 1977;36:770–776.
   PubMed Web of Science ®Google Scholar
• Rai KR, Holland JF, Glidewell OG, et al. Treatment of acute myelocytic leukemia: A study by Cancer And Leukemia Group B. Blood 1981;58:1203–1212.
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell OJ, Wiernik P, et al. Cytosine arabinoside with daunorubicin and adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 1982;60:454–462.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer And Leukemia Group B. Blood 1991;78:2520–2526.
   PubMed Web of Science ®Google Scholar
• Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strate-gies for the treatment of acute nonlymphocytic leukemia: A Cancer And Leukemia Group B study. Blood 1987;69: 1441–1449.
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 1992;10: 1103–1111.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Banks PL, Case DC, Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;15:313–319.
   Google Scholar
• Hansen OP, Pedersen-Bjergaard J, Ellegaard G, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients of acute myeloid leukemia: A Danish National phase III trial. Leukemia 1991;5:510–516.
   PubMed Web of Science ®Google Scholar
• Berman E, Arlin ZA, Gaynor J, et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute non-lympho-cytic leukemia: Results of the L-16M protocol. Leukemia 1989;3:115–121.
   PubMed Web of Science ®Google Scholar
• Arlin Z, Case DC, Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or dauno-rubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990;4: 177–183.
   PubMed Web of Science ®Google Scholar
• Rees JKH, Gray RG, Wheatley K. Dose intensification in acute myeloid leukemia: Greater effectiveness at lower cost. Principle report of the Medical Research Council’s A/VIL9 - study. Br J Haematol 1996;94: 89–98.
   PubMed Web of Science ®Google Scholar
• Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 1996;88:2841–2851.
   PubMed Web of Science ®Google Scholar
• Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710–1717.
   PubMed Web of Science ®Google Scholar
• Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br J Haematol 1992;81:170–177.
   PubMed Web of Science ®Google Scholar
• Büchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group. Blood 1999;93: 4116–4124.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Buchner T. Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol 2001;38\(supp1.6):3–9.
   PubMedGoogle Scholar
• Vaughan WP, Karp JE, Burke PJ. Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 1980;45:859–865.
   Google Scholar
• Burke PJ, Karp JE, Geller RB, et al. Cures of leukemia with aggressive postremission treatment: An update of timed sequential therapy (Ac-D-Ac). Leukemia 1989;3:692–694.
   PubMed Web of Science ®Google Scholar
• Mitus AJ, Miller KB, Schenkein DP, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560–569.
   PubMed Web of Science ®Google Scholar
• Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission out-come in acute myeloid leukemia: A report from the Children’s Cancer Group. Blood 1996;87:4979–4989.
   PubMed Web of Science ®Google Scholar
• Loeb DM, Bowers DC, Civin CI, et al. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. Med Pediatr Oncol 2001;37:365–371.
   PubMedGoogle Scholar
• Burke PJ, Karp JE, Braine HG, et al. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 1977;37:2138–2146.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Karp JE, Vaughan WP. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response. J Natl Cancer Inst 1981;67:529–538.
   Google Scholar
• Karp JE, Burke PJ. Growth response of residual leukemia after initial drug therapy. Cancer Res 1986;46:4205–4207.
   PubMed Web of Science ®Google Scholar
• Karp JE, Donehower RC, Enterline JP, et al. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989;73:24–30.
   PubMed Web of Science ®Google Scholar
• Karp JE, Donehower RC, Dole GB, et al. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. Blood 1987;69: 1134–1140.
   PubMed Web of Science ®Google Scholar
• Vaughan WP, Burke PJ. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model. Cancer Res 198343:2005-2009.
   PubMed Web of Science ®Google Scholar
• Geller RB, Burke PJ, Karp JE, et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989;74:1499–1506.
   PubMed Web of Science ®Google Scholar
• Woods WG, Alonzo TA, Lange BJ, et al. Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): A comparison of outcomes between patients treated on childhood or adult protocols. Blood 2001;98\(suppl. 1): 462a–463a.
   Google Scholar
• Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML:Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004;104:2467–2474.
   PubMed Web of Science ®Google Scholar
• Bishop IF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 199075:27–32.
   Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896–903.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, de Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor (GM-CSF) in younger adults with newly diagnosed acute myeloid leukemia (AML): A trial by the Acute Leukemia French Association (ALFA) group. Blood 2005;106 (suppl. 1):530a.
   Google Scholar
• Bolanos-Meade J, Karp JE, Guo C, et al. Timed sequential therapy of acute myelogenous leukemia in adults: A phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide. Leuk Res 2003;27:313–321.
   PubMed Web of Science ®Google Scholar
• Bradstock KF, Matthews JP, Lowenthal RM, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481–488.
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cyto-genetic subtype. Cancer Res 1998;58:4173–4179.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22,q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17: 3767–3775.
   PubMed Web of Science ®Google Scholar
• Vaughan WP, Karp JE, Burke PJ. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984;64:975–980.
   Google Scholar
• Piaciucci PA, Cuttner J, Holland JF. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. Am J Hematol 1990;35:22–25.
   Google Scholar
• Fiere D, Campos L, Van HV, et al. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. Cancer Treat Rep 1986;70:285–286.
   PubMedGoogle Scholar
• Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991;77:1894–1900.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995;13:11–18.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 1987;69:744–749.
   PubMed Web of Science ®Google Scholar
• Freund M, Link H, Diedrich H, et al. High-dose ara-C and etoposide in refractory or relapsing acute leukemia. Cancer Chemother Pharmacol 1991;28:487–490.
   PubMed Web of Science ®Google Scholar
• Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991;9:1210–1214.
   PubMed Web of Science ®Google Scholar
• Spadea A, Petti MC, Fazi P, et al. Mitoxantrone, etoposide and intermediate-dose ara-C (MEG): An effective regimen for poor risk acute myeloid leukemia. Leukemia 1993;7: 549–552.
   PubMed Web of Science ®Google Scholar
• Larson RA, Day RS, Azarnia N, et al. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukemia in relapse: A Leukemia Intergroup study. Br J Haematol 1992;82:337–346.
   PubMed Web of Science ®Google Scholar
• Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993;11:343–350.
   Google Scholar
• Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: Further evidence for the role of marrow purging by mafosphamide. Leukemia 1991;5:896–904.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Clift RA, Buckner CD, et al. Allogeneic bone marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 1983;61:949–953.
   PubMed Web of Science ®Google Scholar
• Ho AD, Seither E, Ma DD, et al. Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells. Br J Haematol 1987;65:51–55.
   PubMed Web of Science ®Google Scholar
• Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990;50: 5813–5818.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Murray D, Walters R, et al. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 1988;22:205–210.
   PubMed Web of Science ®Google Scholar
• Rivera G, Avery T, Roberts D. Response of L1210 to combination of cytosine arabinoside and VM26 or VP16-213. Eur J Cancer 1975;11: 639–647.
   PubMed Web of Science ®Google Scholar
• Cavalli F, Sonntag RW, Jungi F, et al. VP16-213 mono-therapy for remission induction of small cell lung cancer: A randomized trial using three dosage schedules. Cancer Treat Rep 1978;62:473–475.
   PubMedGoogle Scholar
• Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia. An active and well tolerated regimen. J Clin Oncol 1988;6:213–217.
   PubMed Web of Science ®Google Scholar
• Grant S, Arlin Z, Gewitz D. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 1991;5:336–339.
   Google Scholar
• Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002–2009.
   PubMed Web of Science ®Google Scholar
• Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996;14:2480–2485.
   PubMed Web of Science ®Google Scholar
• Mollgard L, Tidefelt U, Sundman-Engberg B, et al. High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: A pharmacokinetic and clinical study. Ther Drug Monit 1998;20:640–645.
   Google Scholar
• Thomas X, Cambier N, Taksin AL, et al. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leuk Res 2000;24: 957–963.
   PubMed Web of Science ®Google Scholar
• Thomas X, Elhamri M, Chelghoum Y, et al. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: Results of the EMA 2000 trial. Ann Hematol 2005;84: 376–382.
   PubMed Web of Science ®Google Scholar
• Thomas X, Dombret H, Cordonnier C, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000;14:1006–1013.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Castaigne S, Dombret H, et al. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992;80:2176–2181.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Labopin M, Granena A, et al. European survey of bone marrow transplantation in acute promyelocytic leuke-mia (M3). Bone Marrow Transplant 1994;14:293–298.
   PubMed Web of Science ®Google Scholar
• Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARa fusion gene. Blood 1997;90:1321–1325.
   PubMed Web of Science ®Google Scholar
• Roman J, Martin C, Tones A, et al. Absence of detectable PML-RARot fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant 1997;19:679–683.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Lo Cocco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005;90:1231–1235.
   Google Scholar
• Revesz D, Chelghoum Y, Le QH, et al. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: Analysis of prognostic factors. Ann Hematol 2003;82:684–690.
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924–1930.
   PubMed Web of Science ®Google Scholar
• Thomas X, Le QH, de Botton S, et al. Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. Leuk Lymphoma 2005;46: 1007–1016.
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995;332:1678–1683.
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997;90:4710–4718.
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 1998;91:3607–3615.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macro-phage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457–462.
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial che-motherapy for elderly patients with primary acute myelo-genous leukemia. N Engl J Med 1995;332:1671–1677.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281–292.
   PubMed Web of Science ®Google Scholar
• Griffin JD, Young D, Hermann F, et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986;67: 1448–1453.
   PubMed Web of Science ®Google Scholar
• Bhala K, Birkhofer M, Arlin Z, et al. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988;2:810–813.
   PubMed Web of Science ®Google Scholar
• Miyauchi J, Kelleher CA, Wang C, et al. Growth factors influence the sensibility of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:1272–1278.
   PubMed Web of Science ®Google Scholar
• Ben-Ishay Z, Prindull G, Sharon S. Improved prognosis in mice with advanced myeloid leukemia following adminis-tration of GM-CSF and cytosine arabinoside. Leuk Res 1991;15:321–325.
   PubMed Web of Science ®Google Scholar
• Cannistra SA, DiCarlo J, Groshek P, et al. Simultaneous administration of granulocyte-macrophage colony-stimulat-ing factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1989;5: 230–238.
   Web of Science ®Google Scholar
• Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991;77:700–711.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Boogaerts MA, Daenen SMGJ, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15: 3496–3506.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Fenaux P, Reiffers J, et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etopo-side, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993;7:372–377.
   PubMed Web of Science ®Google Scholar
• Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 1999;13: 1214–1220.
   PubMed Web of Science ®Google Scholar
• Bhala K, Holladay C, Arlin Z, et al. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulat-ing factors improve the selectivity of ara-C in vitro against acute myeloid leukemia blasts. Blood 1991;78:2674–2679.
   PubMed Web of Science ®Google Scholar
• He XY, Elson P, Pohlman B, et al. Timed sequential chemotherapy with concomitant granulocyte colony-stimu-lating factor for high-risk acute myelogenous leukemia: A single arm clinical trial. BMC Cancer 2002;2:12.
   PubMed Web of Science ®Google Scholar
• He XY, Pohlman B, Lichtin A, et al. Timed-sequential chemotherapy with concomitant granulocyte colony-stimu-lating factor for newly diagnosed de novo acute myelogenous leukemia. Leukemia 2003;17:1078–1084.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Petti MC, Ardia A, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 1991;27:750–755.
   Google Scholar
• Büchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with and without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985;3:1583–1589.
   PubMed Web of Science ®Google Scholar
• Hann IM, Stevens RE, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML 10). Blood 1997;89:2311–2318.
   Google Scholar
• Hwang wt., Young JH, Gau JP, et al. DAB (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia. Am J Clin Oncol 1992;15:531–534.
   PubMed Web of Science ®Google Scholar
• Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induc-tion treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996;14:2150–2159.
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine ± cytosine arabinoside idarubicin / - all-trans retinoic acid + /- granulocyte colony-stimulating factor in poor prognosis newly-diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:2478–2484.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743–752.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age andolder with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 2005;106:27–34.
   PubMed Web of Science ®Google Scholar
• Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 199891:2722–2730.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Spriggs D, Matsukage A, et al. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β. Cancer Res 1988;48:1494–1498.
   PubMed Web of Science ®Google Scholar
• Bodley AL, Liu LF. Topoisomerases as novel targets for cancer chemotherapy. Biotechnology 1988;6:1315–1319.
   Google Scholar
• Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 199151:1129–1136.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Che-mother Pharmacol 1996;39:109–112.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Adjei A, Donehower RC, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994;12:2193–2203.
   PubMed Web of Science ®Google Scholar
• Crump M, Lipton J, Hedley D, et al. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: A National Cancer Institute of Canada Clinical Trials Group study. Leukemia 1999;13:343–347.
   PubMed Web of Science ®Google Scholar
• Cooper BW, Donaher E, Lazarus HM, et al. A phase I and pharmacodynamic study of sequential topotecan and etopo-side in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. Leuk Res 2003;27:35–44.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Guo C, Gojo I, et al. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: Two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leuk Res 2004;28: 571–577.
   PubMed Web of Science ®Google Scholar
• Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 1994;8:2065–2075.
   Google Scholar
• Hu ZB, Minden MD, McCulloch EA. Post-transcriptional regulation of bc1-2 in acute myeloblastic leukemia: Signifi-cance for response to chemotherapy. Leukemia 1996;10: 410–416.
   PubMed Web of Science ®Google Scholar
• Belhabri A, Thomas X, Wattel E, et al. All-trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non-promyelocytic acute myeloid leukemia: A phase II random-ized trial. Hematol J 2002;3:49–55.
   PubMedGoogle Scholar
• Shah MA, Schwartz GK. Cell cycle mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168–2181.
   PubMed Web of Science ®Google Scholar
• Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces GI arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res 1996356:2973–2978.
   Google Scholar
• Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002;8( suppl.):S32—S37.
   PubMed Web of Science ®Google Scholar
• Cartee L, Wang Z, Decker RH, et al. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001;61:2583–2591.
   PubMed Web of Science ®Google Scholar
• Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various anti-neoplastic agents: The importance of sequence of adminis-tration. Cancer Res 1997;57:3375–3380.
   PubMed Web of Science ®Google Scholar
• Karp JE, Ross DD, Yang W, et al. Timed sequential therapy of acute leukemia with flavopiridol. Clin Cancer Res 2003;9: 307–315.
   PubMed Web of Science ®Google Scholar
• Vankayalapati H, Bearss DJ, Saldanha JW, et al. Targeting aurora2 kinase in oncogenesis: A structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther 2003;2:283–294.
   PubMed Web of Science ®Google Scholar
• Welborra, Kopecky KJ, Meyers FJ, et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia—a Southwest Oncology Group trial. Leukemia 1995;9:1126–1129.
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leuke-mia. Clin Cancer Res 2001;7:1490–1496.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 20033102:2379–2386.
   Google Scholar
• Hiddeman W, Schleyer E, Uhrmeister C, et al. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia—preliminary clinical and pharmacological data of a randomized comparison. Cancer Treat Rev 1990;17:279–285.
   PubMed Web of Science ®Google Scholar
• MacCallum PK, Davis CL, Rohatiner AZ, et al. Mito-xantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 1993;7:1496–1499.
   PubMed Web of Science ®Google Scholar
• Sternberg DW, Aird W, Neuberg D, et al. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermedi-ate-dose cytarabine: A pharmacologically based regimen. Cancer 2000388:2037–2041.
   Google Scholar
• Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 20013112:127–137.
   Google Scholar
• Vogler WR, McCarley DL, Stagg M, et al. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 199448: 1847–1853.
   Google Scholar
• Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2086–2092.
   PubMed Web of Science ®Google Scholar
• Kern W, Aul C, Maschmeyer G, et al. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. Ann Hematol 1998;77:115–122.
   PubMed Web of Science ®Google Scholar